A b s t r a c t
Drug testing is becoming a common practice in many workplace and athletic environments. 1,2 Unanticipated or controversial toxicologic results from urine samples may provoke questions of specimen contamination, mix-up, or intentional tampering. 1, 3 As with tissue specimens, molecular genetic methods may resolve some of these questions. 4, 5 Unfortunately, nuclear DNA (nDNA) is often difficult to retrieve from urine samples owing to a low cellular content in the urine from healthy people and, perhaps, extended storage before molecular testing. 4 There may also exist a number of factors within a person's urine that have a role in diminishing DNA content, including low pH, nucleases from hydrolyzed cells, bacterial contaminants, and drugs and/or metabolites, including nucleoside analogues. 2, [6] [7] [8] In cases in which nDNA cannot be amplified, mitochondrial DNA (mtDNA), which is present in somatic cells in a much higher quantity than nDNA, may be used. 9 The presence of mtDNA within the mitochondrion and its small size and circular nature may also allow for increased protection from degradation, leading to greater amplification efficiency than nDNA. 1 However, conventional methods for mtDNA typing (polymerase chain reaction [PCR] and sequencing of the entire control region) are time-consuming and costly. 10 Our objectives were to evaluate the presence of mtDNA in acellular urine samples and to develop a simple and effective screening method to confirm sources for those samples. It was expected that mtDNA amplification would be much more sensitive than nDNA, given that the number of mtDNA copies in the average cell can be as high as 1,000 times that of nDNA, and it was anticipated that we would find mtDNA in acellular specimen samples owing to lysis of cells from the originating tissue of the specimen. 11 We also hypothesized that real-time PCR using fluorescence resonance energy transfer (FRET) probes designed to cover regions containing more than 1 single nucleotide polymorphism (SNP), with subsequent melting curve analysis, would allow for rapid profile screening. Melting curve analyses with FRET probes allow for observation of hybridization efficiency of the designed probes to the template DNA. 12 In people with template DNA that is identical to the probe sequence, there will be a relatively high melting temperature, whereas in people with an SNP alternative, deletion, or insertion, there will be weaker hybridization, and, thus, less thermal energy will be needed to melt the probe off the template. 12, 13 By using probes that each resolve 2 or 3 SNP positions on 1 PCR product, we expect to be able to rapidly screen specimens and potential sources for matching purposes.
Previous research using melting curve analysis with the LightCycler (Roche Applied Science, Indianapolis, IN) has provided evidence that the Y chromosome may be typed for SNP differences to provide male genotype profiles. 13 One of the obstacles pointed out in that study was a limitation of the LightCycler to perform large multiplexes owing to the limiting number of fluorescent probes. The Y chromosome SNP study demonstrated the usefulness of FRET probes that annealed to a region covering 1 SNP location. We hope to demonstrate increased discrimination power of FRET probes when designed to cover more than 1 SNP locus. Mutational assays have demonstrated that the probe melting temperature shifts vary depending on where the mutation is located within the probe. 14, 15 We hypothesized that a probe covering a region of SNPs would be able to discriminate various SNP changes by the shift observed in the melting temperature. Niederstatter et al 16 demonstrated that real-time PCR can detect heteroplasmy within individuals, and this has been used to quantitate the different allelic states.
Materials and Methods

Sample Collection and DNA Extraction
The demonstration of mtDNA sensitivity and analysis of SNP profiles used a variety of samples (lymph node, 3; peripheral blood, 7; urine, 12; cerebrospinal fluid, 1; and bone marrow, 1) and sample types (fresh, formalin-fixed, and paraffin-embedded, 6; and fine-needle aspirates, 1) that were obtained from the Calgary Laboratory Services Molecular Pathology Laboratory, Calgary, Canada. The 20 urine samples used to establish mtDNA presence in acellular samples were obtained from the Calgary Laboratory Services Toxicology Laboratory following 1 month of storage at 4°C. DNA was extracted from all samples using the QIAamp DNA Mini Kit (Qiagen, Mississauga, Canada). Unlabeled PCR primers were ordered from the University of Calgary Core DNA Services, and FRET probes were purchased from Sigma Proligo (Boulder, CO). Research was carried out under the auspices of the University of Calgary and Calgary Laboratory Services, in accordance with accepted institutional ethical and biosafety standards.
Conventional PCR Amplification
DNA amplification was conducted and optimized using PCR primers for p27 Kip1 (cdkn1b), a single gene nuclear marker, that is commonly used as a control in our laboratory. The p27 amplification (454 base pairs [bp]) was performed in 50-µL reaction volumes with 0.4 µmol/L of each primer (forward primer sequence, 5'-AAACGTGCGAGTGTC-TAACGGGA-3'; reverse primer sequence, 5'-CGCTTCCT-TATTCCTGCGCATTG-3'), 0.2 mmol/L of deoxynucleoside triphosphate (dNTP), 1 U of Red Taq polymerase (SigmaAldrich Canada, Oakville, Canada), 1× Red Taq PCR buffer (Sigma-Aldrich Canada), 1.66 mmol/L of magnesium chloride, and 2 µL of template DNA. The PCR conditions consisted of an initial denaturation at 94°C for 4 minutes, followed by amplification for 32 cycles at 94°C for 30 seconds, 55°C for 30 seconds, and 72°C for 1 minute, with a final extension at 72°C for 7 minutes.
The mitochondrial primer set ❚Figure 1❚ was designed to amplify a region covering 2 clusters of SNPs consisting of 2 and 3 SNPs identified from the Human Mitochondrial Genome Database (http://www.genpat.uu.se/mtDB/) ❚Table 1❚. The primers amplified a 172-bp sequence in the control region that ran from base 16493 to 97, according to the revised Cambridge Reference Sequence. 17, 18 The majority of the amplicon covered a region between hypervariable regions I and II, with an additional 26 bp overlapping hypervariable region II. The mitochondrial amplified samples were also performed in 50-µL reaction volumes with 0.4 µmol/L of forward and reverse primers, Mt-5' and Mt-3', respectively ( Figure 1 ); 0.2 mmol/L of dNTP, 2 mmol/L of magnesium chloride; 1× Red Taq PCR buffer (Sigma-Aldrich Canada); 1 U of Red Taq polymerase (Sigma-Aldrich Canada); and 2 µL of template DNA. The mtDNA PCR conditions consisted of an initial denaturation of 95°C for 1 minute, followed by 32 cycles of amplification at 95°C for 30 seconds, 55°C for 30 seconds, and 72°C for 15 seconds, with a final extension at 72°C for 7 minutes.
Negative and positive control samples were included with the nuclear and mitochondrial urine sample amplifications. The resulting PCR products were run on agarose gels with a 100-bp ladder (New England Biolabs, Pickering, Canada).
Real-Time PCR Amplification
The locations of the 2 probe sets and corresponding anchors are shown in Figure FRET-based PCR was performed on a LightCycler. The amplification conditions for both probe sets included an initial denaturation at 95°C for 10 minutes, followed by 32 cycles of denaturation at 95°C for 10 seconds, annealing at 55°C for 10 seconds, and extension at 72°C for 10 seconds. Fluorescence measurements were obtained at the end of each annealing step. Melting curve analysis followed the final amplification cycle and included a denaturation step at 95°C for 30 seconds followed by cooling to 40°C for 1 minute. Melting curves were then generated by measuring the decrease in fluorescence as the temperature was increased to 80°C at a rate of 0.1°C per second. To account for any cross-talk between the LC-640 and LC-705, fluorescent dye analysis of the probe set 2 reactions involved the use of a previously generated color compensation file (LightCycler Color Compensation Kit, Roche Diagnostics, Laval, Canada). Melting curve peak data were generated by plotting the negative derivative of fluorescence against temperature using LightCycler analysis software, version 3.5 (Roche Diagnostics).
Sequencing
PCR products for sequencing were purified using QIAquick Purification Kit (Qiagen) and quantitated using PicoGreen double-stranded DNA quantitation reagent (Molecular Probes, Eugene, OR) using a TD-700 Fluorimeter (Turner Designs, Sunnyvale, CA). Products were sequenced bidirectionally using the Mt-5' and Mt-3' primers using the ABI Big Dye Terminator Kit (Applied Biosystems, Foster City, CA) and sent to the University of Calgary DNA Sequencing Facility, Calgary, Canada.
mtDNA PCR Sensitivity
Ten-fold serial dilutions of a 100 ng/µL solution of lymph node DNA were prepared with clean, sterile water. The resulting DNA solutions were subjected to conventional and realtime PCR amplification with the nuclear and/or mitochondrial primers.
Analysis of Free mtDNA in Urine
Ten male and 10 female urine samples were obtained and prepared before DNA extraction as follows. The 4 conditions under which DNA was extracted were (1) raw urine, (2) raw urine filtered with a 0.2-µm filter (IC Millex-LG low-protein-binding filter unit, Millipore, Billerica, MA), (3) centrifuged pelleted material (~2,000g for 15 minutes), and (4) 0.2-µm filtered supernatant. All 20 urine samples were subject to DNA extraction under the first 3 conditions, whereas only 5 male and 5 female samples were prepared from 0.2-µm filtered supernatant. Filtration of centrifuged supernatant was performed to reduce the presence of mitochondria in the specimen. Statistical analysis was performed using Graphpad Prism v4 (Graphpad Software, San Diego, CA).
Results
mtDNA Sensitivity
The nDNA marker, p27, exhibited strong amplification with 200, 20, and 2 ng of template DNA; weak amplification with 0.2 ng; and no visibly detectable amplification with 0.02 ng or less of template DNA ❚Figure 2A❚. The mtDNA marker, however, demonstrated robust amplification using 200 to 0.002 ng of template DNA and weak amplification with 0.0002 ng of template DNA ❚Figure 2B❚. Three nuclear short tandem repeat markers, D1S447, D1S457, and D1S243, generating approximately 200-bp amplicons, were also examined and showed even less efficient amplification than the p27 marker (data not shown). In addition, similar results were obtained with real-time PCR using the mitochondrial primer set. ❚Figure 2C❚ shows that amplification is detected when at least 0.002 ng of template DNA is used. All of the assays were standardized to 32 cycles of PCR for comparison.
Occurrence of Free mtDNA in Urine
The female urine samples showed nuclear amplification of 10% of the raw samples and 70% of the pelleted samples but no amplification of the raw filtered samples or the filtered centrifuged supernatant ❚Figure 3❚. In contrast, the male samples did not show nuclear amplification from specimens prepared using any of the treatment conditions. The female urine samples showed mitochondrial amplification in 100% of the pelleted samples, 90% of the raw urine samples, 50% of the raw filtered samples, and 80% of the filtered supernatant. The male samples showed mitochondrial amplification of 90% of the pelleted and raw urine samples and 10% of the raw filtered samples; however, no mtDNA amplification of the filtered supernatant was observed.
For statistical analysis, we pooled the male and female results for each primer set and specimen. In all cases, the mitochondrial primer set was significantly more likely to identify a positive result from the urine specimens than the p27 nuclear primer set (using the Fisher exact test, 1-tailed, data not shown), including the urine centrifugation pellets that should have allowed the best amplification conditions for the p27 primer set (P < .0001). Because the centrifuged and filtered urine specimens were derived from the same 20 raw specimens, it was interesting to observe the loss of nDNA ( Figure  3) following filtering or centrifugation.
Screening a variety of samples using the real-time PCR protocol using probe set 1 revealed 3 melting peak profiles, with melting temperatures of 60.77°C, 63.3°C (± 0.41°C SD), and 68.71°C (± 0.37°C SD) (n = 1, 18, and 12, respectively). ❚Figure 4❚ shows a representative sample of melting curve analysis showing the 3 melting curve peaks. The sequence results for the same samples are shown in ❚Figure 5❚. Sample LN is 100% homologous with the Mt-probe1 sequence and, therefore, produces the melting peak at the highest temperature. In contrast, samples U5 and F1 contain alternative nucleotides at positions 16519 and 16526, respectively, when compared with the probe sequence. The difference in melting peak temperatures between these 2 samples is most likely due to the relative position of the SNP within the probe region. The F1 SNP is closer to the end of the probe, which may contribute to destabilization of hybridization at a lower temperature, producing a melting curve peak slightly lower than that produced by the U5 sample. The frequency of the SNPs reported herein is consistent with rates contained within the Human Mitochondrial Genome Database (Table 1) .
Of the samples sequenced and screened with probe set 2, 4 unique profiles were observed ❚Figure 6❚. The melting temperatures were observed to be 55.79°C and 71.89°C, 65.97°C (± 0.21°C SD), 69.08°C, and 71.86°C (± 0.03°C SD) (n = 1, 4, 1, and 2, respectively). Of particular interest is the result from testing DNA from the urine sample U2, which was heteroplasmic at 2 positions. In Figure 6 , sample U2 produces 2 peaks, one at 55.79°C and the other at 71.89°C. Sequencing results, shown in ❚Figure 7❚, demonstrate the presence of the heteroplasmic sites. The temperatures of the 2 peaks suggest the 2 examples of mtDNA present in this sample include one that is entirely homologous within the probe 2 region to the published revised Cambridge Reference Sequence and another that contains 2 SNPs, 1 at position 64 and 1 at position 73.
Discussion
As expected, the mitochondrial amplifications showed higher sensitivity than the nuclear markers used in the lymph node titration specimens. The mtDNA marker chosen demonstrated a 10 3 higher amplification sensitivity using gel electrophoresis and ethidium bromide staining as a readout, validating the usefulness of mtDNA over nDNA in cellular specimens. This was also confirmed to be transferable to the FRET-based real-time PCR analysis because a similar level of sensitivity was demonstrated when amplifying the mitochondrial sequence.
Overall, mtDNA amplification from the urine samples also seemed more efficient than nDNA amplification because mitochondrial primer sets were significantly more likely to identify a signal in any of the 4 types of urine specimens than the nuclear primer set. Female samples contained more amplifiable nuclear and mtDNA than the male samples, which was anticipated, because females reportedly shed more epithelial cells in their urine. 3 We sought to test the hypothesis that lysed mitochondria contributed "naked" mtDNA to the urine, rather than whole mitochondria, and also to evaluate the effect of common urine processing techniques to determine whether mtDNA could still be detectable in processed specimens. Centrifuging and filtering the raw urine with a 0.2-µm filter was expected to remove cells and debris, including mitochondria (typical size varying from 0.5 to 1.5 µm) that may have been released from previously lysed cells. 19 Extraction and amplification of mtDNA from these samples indicates that there is likely free mtDNA in the urine of males and females; however, it is more frequently found in the urine of females. Although there may be a potential for adsorption of DNA onto the filter, there is also the likelihood of urinary proteins competing for binding sites. Furthermore, it is thought that filter matrices adsorb single-stranded DNA better than double-stranded DNA; hence, we did not expect a significant loss of amplifiable DNA due to binding to the filter. It is unclear why a higher frequency of mtDNA amplification was observed in the female DNA samples that were extracted from the filtered supernatant than in the filtered raw urine. One possibility is that the force of the centrifugation may have been enough to lyse some cells and release the contents into the supernatant. The male filtered supernatant samples did not amplify genomic or mtDNA.
We also sought to test the hypothesis that multiple SNP alleles could be resolved by FRET analysis of a single probeanchor set. The melting curve temperatures for the different mitochondrial genotype profiles were observed to be diverse enough that different SNP profiles could be resolved clearly. The differences in melting temperatures were found to be greater than 1°C for interindividual profiles of the same sequence (data not shown). Naturally, some SNP profiles were found to be more common than others, and the incidence of some of the SNP profiles in our sample population was low. However, the frequency of reported SNPs in our study was consistent with values contained in the Human Mitochondrial Genome Database. In the future, screening larger sample sets will allow for identification of additional melting curve profiles and greater resolution of the SDs for those profiles.
The identification of heteroplasmy at position 73 for sample U2 was not surprising because this position has been reported previously to be frequently observed as heteroplasmic. 20 Preceding studies with fluorescently labeled sequencespecific probes have demonstrated the usefulness of observing dual melting peak results in distinguishing samples from different individuals using mitochondrial markers. 14 The melting curve data for the U2 sample were interesting because they allowed for the determination that the 2 alternative SNP profiles were on the same strand. The higher peak was observed at the same location as another sample known to have the same sequence as the probe, indicating that 1 of the U2 strands was identical to the probe. The lower peak had a melting temperature of approximately 15°C below that temperature, supporting the hypothesis that there were 2 mutations on the other strand, in cis. As a point of interest, the occurrence of heteroplasmy when comparing an unknown with a known sample has been used to increase the genetic discrimination between 2 potentially matching specimens, most famously in the case involving the royal Russian Romanov family. 21 As indicated by the 2 probe results, the real-time PCR may be useful as a screening tool for the mtDNA SNP profiles of different people. The incorporation of additional probe sets to characterize other SNP groups will aid in the discrimination power of this method. A limitation of the LightCycler is the ability of the instrument to read only 2 wavelengths, approximately 640 nm and approximately 705 nm, making the use of different individual assays for a DNA sample necessary to complete the required profiling. The newer LightCycler 480 system allows for detection of 6 dye wavelengths, reducing the required number of capillaries to perform the same tasks, so more simultaneous SNP analyses may be possible with this instrument. By designing 2 probe sets to hybridize to 1 relatively small PCR product, we believe that the efficiency of the reaction may be enhanced by eliminating competing primer sets. For added efficiency, the probe sets were designed to hybridize to opposite template strands to reduce interference.
Our data show that urine specimens are not a reliable source of genomic DNA to use for genetic assays and that mtDNA assays were more sensitive and more useful in evaluating urine specimens. With mtDNA assays, most urine samples could yield amplicons sufficient for sequence analysis and genotyping. Urine that was centrifuged and/or filtered often could still yield a positive mitochondrial genotype, suggesting that naked mtDNA, presumably from lysed cells and lysed mitochondria, was likely present in the specimen. Furthermore, our data show the feasibility of identifying mtDNA polymorphisms using real-time PCR as a quick screen to verify the source of an acellular urine specimen.
Urine specimens are commonly used in testing for a variety of drugs and their metabolites. Some of these analytes, such as antibiotic levels, are for therapeutic purposes, whereas others are to detect illegal or banned substances in the context of athletic, occupational, or government programs. An assay that can be used to verify the source of a urine specimen may be useful to detect situations in which a urine specimen provided is not from the actual test subject or in which a positive result has been obtained and specimen misidentification is alleged.
Studies have shown nDNA and mtDNA testing to be useful in confirming and/or rejecting a concern of contamination or misidentification in other laboratory testing contexts 5, 22 ; however, these are tissue, cytologic, or blood specimens and contain nucleated cells. Our findings suggest that a high proportion of potentially acellular laboratory specimens such as urine samples can contain sufficient mtDNA for analysis. We also demonstrated the potential for developing sensitive and rapid tests for evaluating mitochondrial SNPs using FRET-based PCR and thermal denaturation analysis. Although the FRET-based assay we demonstrated in this work would not be sufficient for confirming the source of a specimen without more amplification and sequencing, we showed it is feasible to develop such assays for multiple SNPs within the same probe area. Future similar assays may be able to resolve sufficient SNPs for specimen confirmation without depending on sequence analysis and, thus, increase convenience in performing mtDNA analysis. 
